Hospital
Montgomery General Hospital, INC
Montgomery General Hospital, INC was paid $9.44M by Medicaid between Jan 2018 and Dec 2024, across 117 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoMONTGOMERY GENERAL HOSPITAL, INC
MONTGOMERY, WV 25136
MONTGOMERY, WV 25136
33aNPI1619913647assigned 06/20/2006
33bProvider typeCritical Access Hospital
28Total paid$9.44M
24GClaims201,252
24DCodes billed117
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in West Virginia
Rank by total paid#7 of 24
Median peer was paid$3.57M
This provider vs. median2.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,360 | $1.49M | |
| 2019 | 20,197 | $750K | |
| 2020 | 31,377 | $1.72M | |
| 2021 | 34,974 | $1.67M | |
| 2022 | 27,425 | $1.36M | |
| 2023 | 34,759 | $1.58M | |
| 2024incomplete | 20,160 | $868K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 7,121 | 6,312 | $1.06M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 5,926 | 4,675 | $1.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.6% | 7,612 | 6,703 | $907K |
| 80053 | Comprehensive metabolic panel | 6.4% | 15,439 | 12,163 | $607K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.4% | 1,451 | 1,215 | $515K |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.2% | 3,092 | 1,730 | $399K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 17,970 | 13,517 | $360K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.9% | 6,563 | 5,127 | $269K |
| 84484 | 2.8% | 5,617 | 4,267 | $264K | |
| 84145 | 2.3% | 2,501 | 2,184 | $218K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.2% | 3,637 | 3,229 | $211K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 1,263 | 1,053 | $196K |
105 more codes
| 36415 | Collection of venous blood by venipuncture | 1.9% | 23,039 | $181K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 5,453 | $152K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.6% | 1,947 | $148K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 3,996 | $148K |
| 80061 | Lipid panel | 1.3% | 3,461 | $124K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 2,707 | $123K |
| 83735 | 1.2% | 5,628 | $115K | |
| 87631 | 1.2% | 620 | $113K | |
| 81001 | 1.2% | 6,137 | $111K | |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 2,226 | $105K |
| 83605 | 1.1% | 4,475 | $104K | |
| 82553 | 1.1% | 2,634 | $103K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 3,403 | $101K |
| G0378 | Hospital observation service, per hour | 1.0% | 941 | $98K |
| 85610 | <1% | 5,630 | $89K | |
| 83880 | <1% | 2,244 | $82K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,594 | $79K |
| 85730 | <1% | 4,804 | $77K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,511 | $75K |
| 82550 | <1% | 4,407 | $71K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,203 | $68K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,910 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,827 | $64K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 628 | $58K |
| 82150 | <1% | 1,757 | $55K | |
| 83690 | <1% | 2,219 | $52K | |
| 80305 | <1% | 505 | $51K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 247 | $49K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 467 | $47K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,840 | $47K |
| 87040 | <1% | 1,177 | $44K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,660 | $41K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 733 | $39K |
| 0099U | <1% | 118 | $38K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 895 | $36K |
| 84439 | <1% | 706 | $35K | |
| 84703 | <1% | 845 | $34K | |
| 93041 | <1% | 671 | $28K | |
| 87070 | <1% | 891 | $25K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 758 | $19K |
| 87486 | <1% | 179 | $17K | |
| 87581 | <1% | 179 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,529 | $17K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 141 | $16K |
| 83525 | <1% | 463 | $16K | |
| 73630 | <1% | 342 | $15K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 291 | $15K |
| 97035 | <1% | 574 | $15K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 228 | $13K |
| 87077 | <1% | 537 | $12K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,437 | $12K |
| 87186 | <1% | 517 | $12K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 264 | $11K |
| 85027 | <1% | 380 | $11K | |
| 87187 | <1% | 517 | $10K | |
| 81003 | <1% | 577 | $10K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 280 | $9K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 394 | $9K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $8K |
| 87205 | <1% | 431 | $7K | |
| 85651 | <1% | 210 | $7K | |
| 73610 | <1% | 138 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 42 | $6K |
| 82607 | <1% | 144 | $5K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,068 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 46 | $5K |
| 97161 | <1% | 86 | $5K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 88 | $5K |
| 82805 | <1% | 134 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 127 | $4K |
| 85379 | <1% | 120 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 54 | $4K |
| 82043 | <1% | 136 | $4K | |
| 83021 | <1% | 251 | $4K | |
| 96376 | <1% | 66 | $3K | |
| 74018 | <1% | 71 | $3K | |
| 36600 | <1% | 131 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 278 | $2K |
| 73030 | <1% | 35 | $2K | |
| 73130 | <1% | 30 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 25 | $1K |
| 73562 | <1% | 15 | $844.00 | |
| 84436 | <1% | 42 | $794.17 | |
| 82800 | <1% | 30 | $726.77 | |
| 90715 | <1% | 13 | $617.19 | |
| 82962 | <1% | 17 | $608.27 | |
| 72110 | <1% | 12 | $570.23 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 149 | $495.84 |
| 99442 | <1% | 66 | $462.34 | |
| 73503 | <1% | 15 | $449.35 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $436.87 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $436.87 |
| 87150 | <1% | 18 | $374.42 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 16 | $344.30 |
| 82140 | <1% | 15 | $337.85 | |
| 87561 | <1% | 18 | $336.07 | |
| 87075 | <1% | 14 | $317.62 | |
| 80320 | <1% | 17 | $213.76 | |
| 81007 | <1% | 12 | $188.15 | |
| 86140 | <1% | 13 | $151.54 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13 | $126.86 |
| 99443 | <1% | 14 | $76.51 | |
| Q2038 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluzone) | <1% | 16 | $32.74 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 24 | $31.99 |
| G0008 | Administration of influenza virus vaccine | <1% | 16 | $7.93 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMURRAY, SHERRI (CFO)
| Provider | Location | Paid |
|---|---|---|
| Montgomery General Hospital, INC | Montgomery, WV | $2.28M |
| Montgomery General Hospital, INC | Montgomery, WV | $582K |
| Montgomery Gen Cahgrp | Montgomery, WV | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.